Cribado de estrongiloidiasis en España en el contexto de la pandemia SARS-CoV-2: resultados de una encuesta sobre diagnóstico y tratamiento.
Por:
Rodríguez-Guardado A, Álvarez-Martínez MJ, Flores MD, Sulleiro E, Torrús-Tendero D, Velasco M and Membrillo FJ
Publicada:
1 jun 2023
Ahead of Print:
15 dic 2021
Resumen:
INTRODUCTION: The generalization of treatment with dexamethasone or other immunosuppressants in patients with SARS-CoV-2 infection may increase the risk of occurrence of severe forms of strongyloidiasis. A nationwide survey was conducted to better understand the diagnostic and therapeutic situation of strongyloidiasis in SARS-CoV-2 co-infected patients in Spain. MATERIALS AND METHODS: A survey was designed and sent to all SEIMC members during February and March 2021. Responses were exported for computer processing to Microsoft Excel 2017 and statistically processed with the free software PSPP. RESULTS: 189 responses were received, of which 121 (64%) were selected for further processing. Eighty-four centers (69.5%) had no specific strongyloidiasis screening protocol. Forty-two centers (34.7%) had serological techniques available in their laboratories and the rest were sent to a reference laboratory. Only 22 centers (18%) screened for strongyloidiasis in SARS-CoV-2 infected patients. A total of 227 cases of strongyloidiasis were diagnosed in patients with SARS-CoV-2 infection. In four cases patients developed a massive hyperinfestation syndrome leading to the death of one patient. CONCLUSION: COVID-19 has highlighted the need to unify screening and treatment protocols for imported pathologies such as strongyloidiosis. Efforts to disseminate knowledge are needed to ensure that this potentially fatal disease is adequately treated in patients with the highest risk of complications, such as those with COVID-19.
Filiaciones:
Rodríguez-Guardado A:
Área de Gestión Clínica Medicina Interna.Hospital Universitario Central de Asturias, Grupo de Microbiología Traslacional. Instituto de Investigación del Principado de Asturias, Spain
Álvarez-Martínez MJ:
Microbiology Department, Hospital Clinic, Barcelona, Spain & Barcelona Institute for Global Health, ISGlobal-Hospital Clinic, Universitat de Barcelona, Spain
Flores MD:
Unidad de Leishmania y Chagas. Centro Nacional de Microbiología. Instituto de Salud Carlos III, Spain
Sulleiro E:
Servei Microbiologia. Hospital Vall d´Hebron. Universitat Autònoma de Barcelona, Barcelona, Spain
:
Unidad de Referencia de Enfermedades Importadas y Salud Internacional. Unidad de Enfermedades Infecciosas. Hospital General Universitario de Alicante. Área de Parasitología, Universidad Miguel Hernández, Spain
Velasco M:
Sección Infecciosas, Medicina Interna. Unidad de Investigación Hospital Universitario Fundación Alcorcón. Madrid. Profesora Asociada Medicina. Universidad Rey Juan Carlos, Spain
Membrillo FJ:
Unidad NRBQ-Infecciosas. Sección de Infecciosas. UAAN. Hospital Central de la Defensa "Gómez Ulla", Madrid, Spain
Bronze, Green Published
|